The subject received any investigational treatment within the past days or prior immunotherapy or antibody therapy within the past days. History of hospitalization in past months for diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic nonketotic syndrome (HHNS) Relapse of pneumocystis carinii pneumonia within the past year before enrollment Patients may not have received cabazitaxel in the past Received PDT during the past months Patients must be at least days past their last course of lymphoma or CLL treatment, at least days past their last course of rituximab treatment. Patients with pre-existing severe or life threatening side effects/conditions from prior therapy or due to other diseases may not be enrolled Has received any systemic bone-seeking radiopharmaceutical in the past History of coronary or vascular stent placed within the past months (may be extended to year if medically indicated per physician discretion). Carcinoma in situ (CIS) in the past in the urinary tract. No increase in steroid dose within the past days Elevated urinary or plasma PBG or ALA values within the past year, Significant clinical change in health in the past days Systemic antineoplastic therapy in the past days (excluding hydroxyurea) Participants have had at least episode of vaso-occlusive crisis (VOC) in the past months. More than VOCs within the past months that required a hospital, emergency room or clinic visit Currently on a leukotriene inhibitor or used within the past months Needing medical attention for serious bleeding in past weeks Patients with solid organ malignancy who have received chemotherapy within the past six months Taxane therapy within the past months ( days) prior to study day Subject has a positive serum Yo antibody (does not need to be repeated if performed in the past) Patients with clinically significant cardiovascular disease: history of ischemic or hemorrhagic stroke within past months; uncontrolled hypertension, on at least repeated determinations on separate days within past months; myocardial infarction or unstable angina within past months; New York Heart Association grade III or greater congestive heart failure, serious cardiac arrhythmia requiring medication, unstable angina pectoris within past months; clinically significant peripheral vascular disease within past months; pulmonary embolism, deep vein thrombosis (DVT), or other thromboembolic event within past months; diagnosed congenital long QT syndrome; any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes); prolonged QTc interval on pre-entry electrocardiogram (> msec); subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration Serious or unstable disease within the past months Tumor staging by standard imaging within the past days (Step subjects only) Subject has received chemotherapy within the past days Erythropoietin or related hormones must not have been administered within the past days Documented cerebral infarction within past months A prior history of Gliadel implantation in the past six months Current or past history of cardiovascular disease (e.g.. past history of myocardial infarction, ischemic cardiomyopathy) unless cardiology consultation and clearance has been obtained for study participation Patient with history of cardiac arrest within the past months A history of syncope with calorie restriction in the past or other medical comorbidity, which would make fasting potentially dangerous A serious, unstable illness, as judged by the Investigator, during the past months before screening/baseline visit including but not limited to: hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or immunologic disease; History of chronic steroid use within the past months Use of treatments in the past months that can affect VMS (e.g., use of oral or transdermal hormone therapy [HT] or contraceptives) Prior cell therapy for relapse within the past days known or suspected past hepatitis C infection (including patients with past interferon 'curative' treatment), Positive urine tetrahydrocannabinol (THC) dipstick test (> ng/mL; indicating marijuana use in the past - hours) Regular or sporadic use of nicotine cigarettes (> cigarettes in the past days) History of any one or more of the following cardiovascular conditions within the past months: No increase in steroid dose within the past days Subject has a history of seizure within the past months of Screening as assessed by neurology examination and history. History of suicide attempt or preparation for attempt within the past years CML treatment resistant mutation(s) (TI, EK/V, YH, FC/V) detected if a testing was done in the past (there is no requirement to perform mutation testing at study entry if it was not done in the past) Dose reductions due to neutropenia or thrombocytopenia in the past months Prior/concurrent therapy including:\r\n* Tamoxifen, raloxifene, letrozole, anastrozole, or exemestane in the past months\r\n* Chemotherapy, biologic therapy (e.g., trastuzumab [Herceptin]), or breast radiotherapy to the breast currently affected by DCIS within the past months\r\n* Any exogenous hormonal therapy including estrogen-, progesterone-, and/or androgen-based agents in the past months\r\n* Phytoestrogens or over-the-counter (OTC) medications with estrogenic or androgenic properties in the past months\r\n* Any black cohosh preparation within the past months History of symptomatic genitourinary stones within the past year Prior surgical endoscopic intervention within the past six months for Spigelman Stage or that may have been down staged to Spigelman or . Patients with a serious cardiac condition within the past months The donor has had: () a trauma or surgery in the past months Use of oral bisphosphonates within the past year Significant circulatory disorders in the past months History of certain cardiovascular conditions within the past months. Stable steroid dose in past weeks History of epistaxis requiring medical/surgical intervention (such as nasal packing) within the past months Important cardiovascular events in the past months. Subjects who have experienced a serious adverse event associated with an RBCx procedure in the past. They have received treatment with orteronel or another lyase inhibitor in the past Patients who have undergone radiation within the past weeks Prior invasive malignancy other than LACC diagnosed within the past months, excluding anal intraepithelial neoplasia, non-melanoma skin carcinoma, or Kaposis sarcoma that has not required systemic chemotherapy within the past months Patients may not have had more than days of treatment with ketoconazole by mouth in the past months History of certain cardiovascular conditions within the past months. Gliadel wafer or wafers implanted within the past weeks any investigational treatment within the past days History of prior treatment with chloroquine for malaria within past months. Smoked an average of less than cigarettes per day during past month No recent history (=< days) of substance abuse (outside of tobacco) defined by National Institute on Alcohol Abuse and Alcoholism (NIAAA) as:\r\n* If male, drinking > alcoholic beverages per week for past month\r\n* If female, drinking > alcoholic beverages per week for past month\r\n* Use of cocaine, heroin, club drugs (i.e., ,-methylenedioxymethamphetamine (MDMA)/ecstasy), methamphetamine, or hallucinogens (e.g., lysergic acid diethylamide [LSD]) at any time during the past month\r\n* Use of marijuana on a weekly basis for the past month Neutropenia (absolute neutrophil count < . x ^/L) at the time of study enrollment (bloodwork is not required if patient did not have chemotherapy within past weeks). Severe psychological impairment (e.g., hospitalization for depressive episode in the past months) Intractable seizures while on adequate anticonvulsant therapymore than seizure per week for the past months Have not experienced a weight reduction >= % within past months Treated with chemotherapy within the past months Subject has received chemotherapy within the past weeks Severe psychological impairment (e.g., hospitalization for depressive episode in the past months) Patients will also be excluded if they report lower extremity (LE) surgery or injury to the LE in the past months or a past medical history of primary hyperparathyroidism; or rhabdomyolysis Chronic treatment with any inhaled steroid for > month in past three months Treatment with montelukast or zafirukast for > month in past three months Treatment with systemic steroids for > month in past three months Chronic nausea over the past weeks Average nausea numeric rating scale >= / over past hours at screening PATIENTS: On scheduled haloperidol for delirium (=< mg in the past h)or rescue haloperidol of >= mg for restlessness/agitation in the past h Subjects who have had radiation to one or both breasts in the past Current or past (< months) engagement in PCST for cancer Phase II: Patients with MBC who\r\n* Have been diagnosed with leptomeningeal disease in the past eight weeks\r\n* Have diagnosed with progressive brain metastases after initial radiation therapy in the past eight weeks\r\n* Have been diagnosed brain metastases and began whole brain radiation therapy in the past eight weeks\r\n* Have an unplanned hospital admission and be discharged within the past eight weeks\r\n* Have been diagnosed with triple negative breast cancer and started second-line therapy within the past eight weeks\r\n* Have received at least three different therapy regimens within a twelve month period and began the third-line therapy regimen within the past eight weeks\r\n* Have HER+ disease and started third-line therapy in the past eight weeks; or\r\n* Have estrogen receptor positive (ER+) disease and started third line chemotherapy in the past eight weeks\r\n* Have begun a treatment clinical trial in the past eight weeks History of incontinence defined as any pad use for urinary leakage in the past months Reports a fall in the past days Undergone laser corrective eye surgery in the past days Current and past history of hypertension Known cardiovascular disease, uncontrolled hypertension, or new cardiac event within the past months Have not received chemotherapy in the past months Current or past (< months) engagement in PCST for cancer Intractable seizures while on adequate anticonvulsant therapymore than seizure per month for the past months Past participation in an MBCT group Reports a fall in the past days Past participation in ACT or formal mindfulness training, and Past history of sexual abuse Hospitalized for psychiatric reasons within the past months Active yoga practice within the past months On regular doses of benzodiazepine or chlorpromazine within the past hours Cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or Patients who have taken melatonin within the past two weeks Treatment with any neuropathic agent including taxane, platinum, vinca alkaloid, or bortezomib chemotherapy in the past months Participants must have been in their spousal relationship for at least the past year Tuberculosis requiring treatment within the past years; all patients must have a negative quantiferon test within weeks prior to starting study drug Treatment with any neuropathic agent including taxane, platinum, vinca alkaloid, or bortezomib chemotherapy in the past months Use of venlafaxine or hypnosis in the past months Prior treatment with finasteride or dutasteride in the past months Patient must have completed curative chemotherapy within past days at a Childrens Oncology Group (COG) institution Chronic, current or recent (within the past three months) use of leukotriene antagonists WHITE, NON-HISPANIC: Participants having had a skin examination within the past year. H/L: Participants having had a skin examination within the past year. Subjects taking long-term systemic steroids defined as greater than months in the past months PHASE I: Use of IT at least times in the past year SOCIAL MEDIA STUDY: Use of IT at least times in the past year to be consistent with the proposed intervention criteria Smokes a minimum of cigarettes per day over the past year. Not have gardened in the past gardening seasons Recent quitters (have not smoked in past days) Use of chemotherapy, trastuzumab, or pertuzumab within the past weeks Use of laxatives within the past days Use of antibiotics within the past days Medications:\r\n* Current anticoagulant use (must discontinue for weeks prior to fine needle aspirate [FNA])\r\n* Taking systemic hormones within two months (eight weeks) prior to screening RPFNA\r\n* Taken tamoxifen, raloxifene, or an aromatase inhibitor within the past months\r\n* Participation on any chemoprevention trial within months Have smoked cigarettes or used any other tobacco product in the past days (i.e., pipe, cigar) and unwilling to stop use for the study period Smoke on >= days of the past days A cardiovascular event in the past month Participants must not have used any tobacco product in the past year PILOT III: Has experienced fatigue within the past seven days Serious or unstable disease within the past months Prior tamoxifen or raloxifene use in the past year. For Chantix:\r\n* Pregnant or breast feeding or planning to become pregnant in the next months\r\n* Currently using nicotine replacement therapy (NRT)\r\n* History of suicide attempt in the past months\r\n* History of thoughts of suicide in the past months\r\n* History of thoughts of harming others in the past months Smoke one or more cigarettes on out of the past days Participants who have had any immunomodulatory treatment in the past months will be excluded Not have gardened in the past gardening seasons Smoke cigarettes of the past days (not including days spent in the hospital) STUDY II: Using e-cigarettes at least once per week over the past month No change in menstrual patterns for the past months preceding the time of registration Zero CPD for past weeks or more CPD for at least out of past months Current smoker (> cigarettes per day for the past months) Smoked regularly in the past year Chronic, current or recent (within the past three months) use of leukotriene antagonists Chronic, current or recent (within the past three months) use of glucocorticoids (systemic, topical and/or nasal sprays) Smoke on >= days of the past days Patients with positive findings on prior imaging within the past weeks are eligible For traditional cigarettes (TC) smokers, daily TC smoking in the past months, at least cigarettes per day, with no EC exposure in the past months For electronic cigarettes (EC) users, daily EC use in the past months, at least sessions per day, with no TC exposure in the past months No anti-estrogen therapy for desmoid tumor within the past months Subject has received a Feraheme (ferumoxytol) Injection within the past months. Prior diagnosis of asthma, OR use of an inhaler in past three years to treat or prevent bronchospasm History of symptomatic genitourinary stones within the past year Major changes in eating habits within the past months Other tobacco use within the past year for consecutive days or times Postmenopausal (no menstrual cycle in the past months) Chemotherapy/radiation within the past year Report tobacco use within the past days Have resided (and intend to continue to reside) in the same home as the child/ren for the past months (and the next months) Patients who have already done the ESAS in the past recent history of cardiovascular distress (heart attack in past year; arrhythmia; uncontrolled hypertension) History of parathyroid disorder or history or malignancy-associated hypercalcemia requiring therapy in the past months Participants must not have had chemotherapy within the past days Cancer treatment within the past weeks